In This Section      
 

Search Results

Title:
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155).
Protocol Number:
J1652
Phase:
Phase I
Physician:
Nina Wagner-Johnston
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
To evaluate the safety of pembrolizumab (MK-3475) in combination with dinaciclib (MK-7965) in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or diffuse large B-cell lymphoma (DLBCL). This is a phase 1b study for dose escalation.
Eligibility:
Age 18+. Must have CLL, DLBCL, or MM. Patients with CLL must have previously received at least 1 prior therapy. Patients with DLBCL must have previously received at least 2 lines of therapy. Patients with MM must have previously recieved 2 or more anti-myeloma treatment lines and must have failed their last line.
Treatment:
Subjects will participate in the study for up to approximately 26 months, including receipt of study drug for approximately 24 months.
Population:
Adult
Last Update
03/05/2019 05:03 AM